Vidya Therapeutics Australia

Vidya Therapeutics is a clinical-stage biotechnology company focused on developing highly selective small molecule inhibitors for autoimmune and inflammatory diseases. The company's lead candidate, VT-101, is a potent and selective inhibitor of Tyrosine Kinase 2 (TYK2), designed to block the signaling of key pro-inflammatory cytokines while avoiding the off-target effects associated with broader Janus kinase inhibition. Vidya Therapeutics Australia serves as the company's regional entity for conducting clinical research, leveraging Australia's efficient regulatory environment and R&D tax incentives. The company utilizes advanced structure-based drug design to create therapies that offer improved safety and efficacy profiles for patients with conditions such as psoriasis and inflammatory bowel disease. Headquartered in the United States, Vidya is backed by prominent life science investors including Westlake Village BioPartners and Vida Ventures.